WINSUNBIO
839729
HIGO
872351
DRIVE
838275
4
Shanghai Menon Animal Nutrition Technology
301156
5
Nanjing Railway New Technology
301016
CN Stock MarketDetailed Quotes
688506 Sichuan Biokin Pharmaceutical
- 250.25
- +3.26+1.32%
Market Closed Apr 3 15:00 CST
100.35BMarket Cap27.07P/E (TTM)
251.58High241.01Low11.35KlotVolume246.80Open246.99Pre Close280.54MTurnover1.23%Turnover Ratio27.07P/E (Static)401.00MShares254.0052wk High25.82P/B23.04BFloat Cap113.8952wk Low296.39Limit Up92.07MShs Float254.00Historical High197.59Limit Down4.28%Amplitude28.75Historical Low--Dividend TTM247.16Avg Price5.67KlotAsk--Div YieldTTM100Lot Size4.82KlotBid
Sichuan Biokin Pharmaceutical Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | 939.93%6.1B | 1,324.20%5.99B | 1,926.59%5.89B | 4,227.10%5.8B | 13.71%586.2M | 12.24%420.71M | 17.68%290.76M | 12.95%134.05M | -38.89%515.53M | -38.31%374.83M |
| Refunds of taxes and levies | -85.73%4.13M | -79.67%4.09M | 2.37%3.42M | 274.39%3.42M | -13.79%28.99M | -30.55%20.11M | -87.10%3.34M | 1,625.97%914.39K | 159.15%33.62M | 288.58%28.95M |
| Cash received relating to other operating activities | 234.56%306.21M | 180.94%156.06M | 322.72%75.79M | 267.65%25.28M | 41.76%91.52M | 391.24%55.55M | 80.57%17.93M | 90.21%6.88M | -0.09%64.56M | -81.14%11.31M |
| Cash inflows from operating activities | 806.51%6.41B | 1,139.39%6.15B | 1,813.81%5.97B | 4,009.65%5.83B | 15.15%706.71M | 19.58%496.36M | 10.28%312.03M | 15.93%141.84M | -33.38%613.71M | -38.51%415.09M |
| Goods services cash paid | 39.21%89.12M | -2.56%62.79M | 38.39%44.18M | 68.39%26.1M | 14.41%64.02M | 133.50%64.44M | 136.13%31.92M | 57.19%15.5M | -52.91%55.95M | 4.17%27.6M |
| Staff behalf paid | 67.62%513.14M | 41.88%326.32M | 22.46%201.45M | 34.28%113.53M | 26.83%306.13M | 28.65%230M | 35.61%164.51M | 30.94%84.55M | 20.96%241.38M | 18.27%178.77M |
| All taxes paid | 454.49%432.33M | 273.12%276.51M | 150.95%121.25M | -4.75%30.84M | 11.03%77.97M | 39.98%74.11M | 28.74%48.32M | 87.99%32.38M | -38.42%70.22M | -41.91%52.94M |
| Cash paid relating to other operating activities | 50.26%1.31B | 63.14%991.73M | 47.58%576.07M | 41.78%279.74M | 73.12%873.95M | 59.52%607.89M | 50.86%390.33M | 56.74%197.3M | -19.08%504.81M | -17.55%381.08M |
| Cash outflows from operating activities | 77.58%2.35B | 69.73%1.66B | 48.48%942.95M | 36.54%450.22M | 51.55%1.32B | 52.47%976.44M | 47.32%635.08M | 51.58%329.74M | -17.41%872.36M | -12.39%640.39M |
| Net cash flows from operating activities | 759.57%4.06B | 1,036.21%4.49B | 1,656.60%5.03B | 2,962.70%5.38B | -137.91%-615.35M | -113.08%-480.07M | -118.04%-323.06M | -97.40%-187.9M | -91.55%-258.65M | -302.72%-225.31M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --20.05M | ---- | ---- |
| Cash received from returns on investments | 786,726.56%30.68M | 869,974.30%33.92M | ---- | ---- | --3.9K | --3.9K | --3.9K | --3.9K | ---- | ---- |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | 74.12%104.28K | -91.74%1.4K | -91.74%1.4K | -91.74%1.4K | 482.93%59.89K | 76.79%16.95K | 76.79%16.95K | --16.95K | -85.47%10.27K | -85.88%9.59K |
| Cash received relating to other investing activities | 8,980.03%1.82B | 7,976.16%1.62B | ---- | ---- | --20.05M | --20.05M | --20.05M | ---- | ---- | ---- |
| Cash inflows from investing activities | 9,104.26%1.85B | 8,136.78%1.65B | -99.99%1.4K | -99.99%1.4K | 195,685.09%20.11M | 209,242.61%20.07M | 209,242.61%20.07M | --20.07M | -100.00%10.27K | -100.00%9.59K |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | 2.34%83.86M | -25.16%38.45M | -46.06%21.88M | -68.56%9.19M | 137.12%81.94M | 74.91%51.38M | 56.18%40.57M | 42.97%29.22M | -22.52%34.56M | -11.39%29.38M |
| Cash paid to acquire investments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --20.05M | ---- | ---- |
| Cash paid relating to other investing activities | 21,510.54%4.33B | 11,436.28%2.31B | 7,976.16%1.62B | ---- | --20.05M | --20.05M | --20.05M | ---- | ---- | ---- |
| Cash outflows from investing activities | 4,230.62%4.42B | 3,191.84%2.35B | 2,607.24%1.64B | -81.36%9.19M | 195.14%101.99M | 143.16%71.43M | 133.36%60.62M | 141.08%49.27M | -89.33%34.56M | -90.59%29.38M |
| Net cash flows from investing activities | -3,033.35%-2.57B | -1,259.52%-698.29M | -3,947.22%-1.64B | 68.54%-9.18M | -137.00%-81.88M | -74.89%-51.36M | -56.16%-40.55M | -42.87%-29.2M | -122.12%-34.55M | -117.52%-29.37M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --907.47M | ---- |
| Cash from borrowing | 325.27%1.9B | 859.16%1.13B | 363.04%545M | 233.33%100M | 19.39%447.7M | -55.58%117.7M | 56.93%117.7M | 0.00%30M | 54.96%375M | 102.29%265M |
| Cash received relating to other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 54.23%92.54M | 54.23%92.54M |
| Cash inflows from financing activities | 325.27%1.9B | 859.16%1.13B | 363.04%545M | 233.33%100M | -67.44%447.7M | -67.08%117.7M | -29.75%117.7M | -65.09%30M | 355.30%1.38B | 87.19%357.54M |
| Borrowing repayment | 116.47%518.96M | 113.08%242.98M | -25.55%67.02M | -66.65%14.01M | 48.91%239.74M | 14.03%114.03M | 125.05%90.02M | 5.03%42.01M | -11.05%161M | -33.77%100M |
| Dividend interest payment | 104.34%38.36M | 95.32%25.41M | 59.76%14.39M | 39.04%6.24M | 49.17%18.77M | 58.38%13.01M | 82.91%9.01M | 92.28%4.49M | -53.34%12.59M | -67.49%8.22M |
| Cash payments relating to other financing activities | -26.06%72.72M | -18.18%63.81M | -43.48%28.93M | -39.46%24.97M | 58.58%98.34M | 48.52%77.98M | 110.80%51.19M | 190.00%41.25M | 1,054.75%62.01M | 2,594.30%52.51M |
| Cash outflows from financing activities | 76.55%630.04M | 62.03%332.2M | -26.54%110.34M | -48.47%45.22M | 51.47%356.86M | 27.56%205.02M | 117.05%150.22M | 55.14%87.74M | 10.43%235.6M | -9.82%160.72M |
| Net cash flows from financing activities | 1,302.30%1.27B | 1,012.39%796.73M | 1,436.73%434.66M | 194.87%54.78M | -92.03%90.84M | -144.37%-87.32M | -133.07%-32.52M | -296.52%-57.74M | 1,185.22%1.14B | 1,440.45%196.82M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | 1,978.47%49.19M | -9,842.08%-62.05M | 9,336.57%14.18M | -5,151.99%-4.44M | -1,119.51%-2.62M | -121.21%-624.09K | -120.21%-153.51K | -238.09%-84.51K | 133.75%256.85K | 1,316.42%2.94M |
| Net increase in cash and cash equivalents | 562.45%2.82B | 831.51%4.53B | 1,068.10%3.84B | 2,071.50%5.42B | -171.95%-609M | -1,027.88%-619.38M | -428.10%-396.28M | -219.02%-274.92M | 676.51%846.47M | -144.22%-54.92M |
| Add:Begin period cash and cash equivalents | -60.86%391.69M | -61.02%391.69M | -60.86%391.69M | -60.86%391.69M | 548.87%1B | 551.49%1B | 548.87%1B | 548.87%1B | 241.11%154.22M | 241.11%154.22M |
| End period cash equivalent | 719.01%3.21B | 1,177.41%4.92B | 599.52%4.23B | 700.78%5.81B | -60.86%391.69M | 288.05%385.36M | 663.30%604.42M | 966.62%725.77M | 548.87%1B | -41.38%99.31M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | -- | -- |
| Auditor | -- | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.